Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca , Pepparedsleden 1, Mölndal, 431 83, Sweden.
AstraZeneca MPI Satellite Unit, Department of Chemical Biology, Max Planck Institute of Molecular Physiology , Dortmund 44202, Germany.
J Med Chem. 2016 Nov 10;59(21):9599-9621. doi: 10.1021/acs.jmedchem.6b00376. Epub 2016 Jul 29.
Over the past decade, foldamers have progressively emerged as useful architectures to mimic secondary structures of proteins. Peptidic foldamers, consisting of various amino acid based backbones, have been the most studied from a therapeutic perspective, while polyaromatic foldamers have barely evolved from their nascency and remain perplexing for medicinal chemists due to their poor drug-like nature. Despite these limitations, this compound class may still offer opportunities to study challenging targets or provide chemical biology tools. The potential of foldamer drug candidates reaching the clinic is still a stretch. Nevertheless, advances in the field have demonstrated their potential for the discovery of next generation therapeutics. In this perspective, the current knowledge of foldamers is reviewed in a drug discovery context. Recent advances in the early phases of drug discovery including hit finding, target validation, and optimization and molecular modeling are discussed. In addition, challenges and focus areas are debated and gaps highlighted.
在过去的十年中,折叠体逐渐成为模拟蛋白质二级结构的有用结构。从治疗的角度来看,基于各种氨基酸的肽折叠体是研究最多的,而聚芳族折叠体几乎没有从其起源发展,并且由于其较差的类药性,对药物化学家来说仍然令人费解。尽管存在这些限制,此类化合物仍可能为研究具有挑战性的靶标或提供化学生物学工具提供机会。折叠体候选药物进入临床的潜力仍然是一个挑战。尽管如此,该领域的进展已经证明了它们在发现下一代治疗药物方面的潜力。从这个角度来看,在药物发现的背景下对折叠体的现有知识进行了综述。讨论了药物发现早期阶段(包括命中发现、靶标验证、优化和分子建模)的最新进展。此外,还讨论了挑战和重点领域,并突出了差距。